2-chloro-4-(5-fluoro-2-methoxyphenyl)pyrimidine | 954237-04-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-chloro-4-(5-fluoro-2-methoxyphenyl)pyrimidine
• CAS: 954237-04-8
• 化学式: C₁₁H₈ClFN₂O
• 分子量: 238.649
• InChiKey: LJDYPDFYDYUVQU-UHFFFAOYSA-N

物化性质

• 沸点：
  372.9±27.0 °C(Predicted)
• 密度：
  1.316±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-chloro-4-(5-fluoro-2-methoxyphenyl)pyrimidine 、 磺胺异噁唑 在 盐酸 作用下， 以 1,4-二氧六环 、 叔丁醇 为溶剂， 反应 5.0h， 生成 N-(3,4-dimethylisoxazol-5-yl)-4-{[4-(5-fluoro-2-methoxyphenyl)pyrimidin-2-yl]amino}benzenesulfonamide
  参考文献：
  名称：

  Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma

  摘要：

  Cyclin-dependent kinases (CDKs) and Polo-like kinases (PLKs) play key role in the regulation of the cell cycle. The aim of our study was originally the further development of our recently discovered polo-like kinase 1 (PLK1) inhibitors. A series of new 2,4-disubstituted pyrimidine derivatives were synthesized around the original hit, but their PLK1 inhibitory activity was very poor. However the novel compounds showed nanomolar CDK9 inhibitory activity and very good antiproliferative effect on multiple myeloma cell lines (RPMI-8226). (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.01.002
• 作为产物：
  描述：

  2,4-二氯嘧啶 、 5-氟-2-甲氧基苯硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 4.0h， 生成 2-chloro-4-(5-fluoro-2-methoxyphenyl)pyrimidine
  参考文献：
  名称：

  Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma

  摘要：

  Cyclin-dependent kinases (CDKs) and Polo-like kinases (PLKs) play key role in the regulation of the cell cycle. The aim of our study was originally the further development of our recently discovered polo-like kinase 1 (PLK1) inhibitors. A series of new 2,4-disubstituted pyrimidine derivatives were synthesized around the original hit, but their PLK1 inhibitory activity was very poor. However the novel compounds showed nanomolar CDK9 inhibitory activity and very good antiproliferative effect on multiple myeloma cell lines (RPMI-8226). (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.01.002

文献信息

• [EN] PYRIMIDINE DERIVATIVES AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE<br/>[FR] DÉRIVÉS DE PYRIMIDINE COMME ACTIVATEURS DE GUANYLATE CYCLASE SOLUBLE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2010015653A1

  公开（公告）日：2010-02-11

  Disclosed are compounds of formula (I) and or salts thereof which activate soluble guanylate cyclase (sGC), pharmaceutical compositions containing them, their use in the manufacture of a medicament for teating cardiovascular diseases, and processes for their preparation.

  揭示了公式（I）的化合物及其盐，这些化合物激活可溶性鸟苷酸环化酶（sGC），包含它们的药物组合物，它们在制造用于治疗心血管疾病的药物中的应用，以及它们的制备方法。
• Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma
  作者：Zsófia Czudor、Mária Balogh、Péter Bánhegyi、Sándor Boros、Nóra Breza、Judit Dobos、Márk Fábián、Zoltán Horváth、Eszter Illyés、Péter Markó、Anna Sipos、Csaba Szántai-Kis、Bálint Szokol、László Őrfi

  DOI：10.1016/j.bmcl.2018.01.002

  日期：2018.2

  Cyclin-dependent kinases (CDKs) and Polo-like kinases (PLKs) play key role in the regulation of the cell cycle. The aim of our study was originally the further development of our recently discovered polo-like kinase 1 (PLK1) inhibitors. A series of new 2,4-disubstituted pyrimidine derivatives were synthesized around the original hit, but their PLK1 inhibitory activity was very poor. However the novel compounds showed nanomolar CDK9 inhibitory activity and very good antiproliferative effect on multiple myeloma cell lines (RPMI-8226). (C) 2018 Elsevier Ltd. All rights reserved.